#USA #New York #Securities Fraud #Rosen Law Firm #ADMA Biologics

ADMA Biologics Investors Alert: Join the Class Action Lawsuit

On June 21, 2026, The Rosen Law Firm, a renowned global law firm specializing in investor rights, issued an important announcement for purchasers of ADMA Biologics, Inc. (NASDAQ: ADMA) securities. This announcement impacts those who acquired shares during the period from August 9, 2024, to March 25, 2026, inclusive.

Key Dates and Actions Required

Those affected by the alleged securities fraud at ADMA Biologics should act promptly, as the deadline to serve as lead plaintiff in this class action lawsuit is August 10, 2026. A lead plaintiff plays a significant role in guiding the lawsuit on behalf of other aggrieved investors. For those interested in participating, The Rosen Law Firm has set up a straightforward process for joining this class action. Interested parties can visit Rosen's official page or contact Phillip Kim, Esq. at 866-767-3653 for more information.

Understanding the Allegations

The essence of the lawsuit stems from accusations that ADMA Biologics made materially false statements and failed to disclose critical information. Specifically, the firm alleges that during the Class Period:

1. Undisclosed Related Party Transactions: ADMA Biologics engaged in undisclosed transactions that could impact investor perception and company valuation.
2. Channel Stuffing: This practice was allegedly utilized to artificially inflate revenue figures, misleading investors about the company's true financial health.
3. Inadequate Internal Controls: The company reportedly lacked the necessary internal controls that are vital for accurate financial reporting.
4. Material Misleading Statements: The combination of the above actions rendered various statements made by the defendants about ADMA Biologics' business and prospects materially false and misleading.

Why Rosen Law Firm?

Rosen Law Firm is not just another name in the list of law firms; it possesses significant experience and a demonstrable track record in handling securities class actions. Below are some notable credentials:

• - The firm achieved one of the largest settlements against a Chinese company in the history of securities class actions.
• - It was ranked #1 by ISS Securities Class Action Services for the number of settlements in 2017, and it has maintained a position within the top four ranks every year since 2013.
• - To date, Rosen Law Firm has successfully recovered hundreds of millions of dollars for investors, marking a stellar performance in the legal landscape.
• - Founding partner Laurence Rosen has been named as a leader in the plaintiffs’ bar by Law360, showcasing the firm's credibility and capability.

How to Proceed

Investors who purchased ADMA Biologics securities during the specified Class Period have a substantial opportunity not only to seek redress but also to potentially lead the case against the company. It is important to highlight that no class has yet been certified, meaning interested parties must select counsel independently to ensure proper representation.

For those opting to join the class action, the Rosen Law Firm advises legal wisdom in selecting qualified counsel with relevant experience, as many firms may merely act as intermediaries rather than robust litigating partners in securities class actions.

The opportunity here is real. By standing together, investors can assert their rights against corporate misconduct and seek compensation for losses incurred as a result of misleading practices by ADMA Biologics. Don't miss out on this chance to make your voice heard and possibly reclaim your lost investments. Stay informed by following The Rosen Law Firm on their social media platforms for updates as the case develops.

For more information about the class action or to join, please visit: Rosen's official page.

Contact Information

• - Law Firm: The Rosen Law Firm, P.A.
• - Email: [email protected]
• - Phone: 1-866-767-3653

Conclusion

This is a pivotal moment for investors in ADMA Biologics. With the law firm’s proven track record and supportive infrastructure, joining this class action lawsuit could provide a pathway to justice and recovery for all affected shareholders. Time is of the essence, and an informed approach is critical for success in the pursuit of compensation.